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Abstract
Background: Dizziness is a very common symptom that often leads to reduced quality of life, anxiety and
emotional distress, loss of fitness, lack of confidence in balance, unsteadiness and an increased risk of
falling. Most dizzy patients are managed in primary care by reassurance and medication to suppress
symptoms. Trials have shown that chronic dizziness can be treated effectively in primary care using a self-
help booklet to teach patients vestibular rehabilitation exercises that promote neurological adaptation and
skill and confidence in balance. However, brief support from a trained nurse was provided in these trials,
and this model of managing dizzy patients has not been taken up due to a lack of skills and resources in
primary care. The aim of this trial is to evaluate two new alternative models of delivery that may be more
feasible and cost-effective.
Methods/Design: In a single blind two-centre pragmatic controlled trial, we will randomise 330 patients
from 30 practices to a) self-help booklet with telephone support from a vestibular therapist, b) self-help
booklet alone, c) routine medical care. Symptoms, disability, handicap and quality of life will be assessed
by validated questionnaires administered by post at baseline, immediately post-treatment (3 months), and
at one year follow-up. The study is powered to test our primary hypothesis, that the self-help booklet with
telephone support will be more effective than routine care. We will also explore the effectiveness of the
booklet without any support, and calculate the costs of treatment in each arm.
Discussion: If our trial indicates that patients can cost-effectively manage their dizziness in primary care,
then it can be easily rolled out to relieve the symptoms of the many patients in primary care who currently
have chronic, untreated, disabling dizziness. Treatment in primary care may reduce the development of
psychological and physical sequelae that cause handicap and require treatment. There is also the potential
to reduce the cost to the NHS of treating dizziness by reducing demand for referral to secondary care for
specialist assessment and treatment.
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Background
Dizziness has a prevalence of up to 25% in the commu-
nity [1-4], and 1 in 10 working age adults report some
degree of handicap due to dizziness [3]. Dizziness is a
more severe problem for older people; more than 1 in 5
people aged over 60 have current dizziness that has led to
significant disability, medical consultation or medication
use [5]. Dizziness is also associated with falls, fear of fall-
ing and loss of independence in older people [6,7].
The most common cause of dizziness in primary care is
peripheral vestibular disorder, and serious sinister pathol-
ogy in patients with no other symptoms is very rare [2,8-
12]. Most patients are therefore managed in primary care
[1,9,13,14] by reassurance and medication for sympto-
matic relief [9,11,13,15,16]. However, living with chronic
dizziness often entails avoiding all physical activities and
situations that might provoke dizziness, leading to clini-
cally significant limitations in physical functioning,
reduced quality of life, emotional distress, loss of fitness,
unsteadiness and lack of confidence in balance (especially
as patients get older), and vulnerability to falling [17-20].
Anxiety about symptoms can contribute to this vicious
cycle of chronic dizziness and distress, and a significant
minority of patients develop secondary symptoms of
panic and agoraphobia [21,22]. Moreover, reviews of the
management of dizziness have concluded that no medica-
tion has well-established value or is suitable for long-term
use, and vestibular rehabilitation (VR) is now recom-
mended as the treatment of choice [11,16,23-27].
VR involves the patient carrying out graded exercises for
10-20 minutes daily for 6 to 12 weeks, consisting of spe-
cific eye, head and body movements that stimulate the
vestibular system so as to promote neurological adapta-
tion to the altered input from the damaged labyrinth
[15,28,29]. Performing these exercises also helps patients
to overcome fear and avoidance of activities that provoke
dizziness, and regain skill and confidence in balance,
reducing the risk of falls [30,31]. Small scale studies have
provided some evidence that VR may be an effective treat-
ment for dizziness due to a variety of conditions, includ-
ing peripheral and central vestibular disorder, benign
paroxysmal positional vertigo, whiplash-associated dizzi-
ness, acute vertigo, surgery for acoustic neuroma, anxiety,
head injury, and dizziness in the elderly [32-40]. A
Cochrane review of 21 randomised clinical trials of VR for
dizziness due to a range of unilateral peripheral vestibular
disorders reported that almost all the trials included in the
review demonstrated that VR was a more effective treat-
ment for dizziness than other interventions [25].
Access to VR in the UK usually involves referral to second-
ary care for a consultation and neuro-otological assess-
ment, often followed by referral to a physiotherapist for
VR. Between 9% and 19% of dizzy patients are currently
referred to secondary care [1,13]. Two trials, however,
have shown that chronic dizziness can also be treated
effectively in primary care, using a self-help booklet that
instructs patients how to carry out VR with brief support
from a trained nurse [41,42]. A non-blind randomized
controlled trial provided a preliminary positive evalua-
tion of the efficacy of providing the booklet together with
two visits from a trained nurse [41]. The second study was
a single blind randomised pragmatic trial of the effective-
ness of the booklet, supported by a single session of reha-
bilitation delivered by nurses working in primary care and
two follow-up phone calls [42]. Patients with chronic diz-
ziness from 20 practices were randomised to VR (n = 83)
or usual medical care (n = 87). Post-treatment, improve-
ment in the treatment group was significantly greater than
in the usual medical care group on all primary outcome
measures (including reported symptoms, disability and
handicap and objective measurement of postural stabil-
ity), and was maintained at six months; 67% of treated
patients reported clinically significant improvement,
compared with 38% controls (relative risk = 1.78, 95%
C.I. 1.31 to 2.42). Nearly four times as many treated
patients as controls had no provoked symptoms at all.
These results are comparable to those achieved in second-
ary care [25,27].
A further study has investigated whether the booklets are
effective if no support is provided [43]. The study was car-
ried out in a sample of people with Ménière's disease, a
severe and recurrent form of vestibular disorder for which
VR can only provide temporary relief from residual dizzi-
ness in between spontaneous attacks of symptoms. Never-
theless, at 6-month follow-up, 45 (37.5%) of the VR
group reported improvement compared with 19 (15.8%)
controls; the relative probability of improvement com-
pared with controls was 2.37 (95% C.I. 1.48 -3.80). Post-
treatment, the rehabilitation group had reduced symp-
toms, anxiety, handicap, and negative beliefs about dizzi-
ness, while the control group showed no improvement.
However, reported adherence levels were low and strongly
related to outcome. Giving patients the means to manage
their symptoms of dizziness in primary care is consistent
with the Department of Health initiative to encourage
self-care [44] where this can bring benefit to patients and
savings for the NHS.
Rationale and aims
Despite the consensus that VR is the treatment of choice
for patients with dizziness of peripheral vestibular origin
[23,27], few eligible patients are currently offered VR.
Only 2% to 13% of dizzy patients seen by GPs eventually
receive VR, of whom around 70% are seen in ENT [1,13].
Yardley and colleagues [42] found that only 3% of partic-
ipants (5/170) had previously been offered VR, despite aBMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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mean duration of dizziness of 8 years, yet 2/3 of partici-
pants benefited from it. Although it has been demon-
strated that the self-help booklet is effective when
combined with support from a practice nurse, this model
of managing dizzy patients has not been taken up in pri-
mary care due to a lack of skills and resources. The primary
aim of the current trial is to determine whether VR can be
delivered to dizzy patients in primary care in a feasible,
safe and cost-effective way. Two new alternative models of
delivery of VR in primary care will be evaluated that may
be more feasible and cost-effective.
The first model will examine whether using the self-help
booklet with telephone support from a vestibular thera-
pist can be effective. This model of delivery is more feasi-
ble than the previous model to roll out across the NHS, as
there are already many trained vestibular therapists cur-
rently providing therapy in secondary care, whereas very
few general practices can provide expert support for VR.
Patients may also benefit from having support from an
expert vestibular therapist rather than a nurse with limited
training. However, remote support from an unknown per-
son might be less effective than close contact with a famil-
iar nurse. The cost of referring patients to secondary care
for diagnostic evaluation prior to VR is substantial. The
cost varies widely depending on the procedures under-
taken, but for patients referred for VR are likely to average
around £250 (this figure is based on typical costs of a
medical consultation with a senior hospital doctor [45],
and the cost of a vestibular assessment and one session of
rehabilitation). Expert telephone support for VR can be
provided for around £40 an hour (since typical costs for
physiotherapists and similar health professionals are no
more than £35/hour [45]). Consequently, using our new
proposed model of delivery, it should be possible to pro-
vide six primary care patients with VR with expert tele-
phone support for less than the cost of referring one
patient to secondary care for VR. We predict that by pro-
viding treatment and expert support in primary care, the
number of patients requiring referral will be reduced,
resulting in a lower cost of managing dizziness.
Having previously demonstrated that the self-help book-
let alone has a small effect on symptoms and handicap in
people with Ménière's disease [43], our second model pre-
dicts that it will also be effective in a primary care sample
of patients with less severe, recurrent symptoms. In the
previous trial, over a third of patients were able to success-
fully self-treat using the booklet without support. The cost
of providing only the self-help VR booklet to patients in
primary care is negligible (less than 50 p), and is compa-
rable to the cost of a single prescription of the types of
medication commonly used for dizziness symptoms.
Since this is a very low cost model of delivery it may well
prove cost-effective if a similar proportion of patients ben-
efit from it, and even if only a small proportion of patients
can be managed in primary care by the self-help booklet
alone, this may still result in substantial savings for the
NHS. Because the effect size of using the booklet alone is
likely to be small we are unable to power the trial for a
definitive test of this hypothesis, but this study will allow
us to estimate the likely treatment effect size in a primary
care population (which has not yet been established),
which would permit a definitive trial in the future.
Provision of the self-help booklet (either with or without
telephone support) may therefore represent a cost-effec-
tive first stage of patient management, reserving referral to
secondary care for patients who require further assess-
ment and therapeutic input.
￿ Hypothesis 1: Provision of a self-help booklet teaching
VR exercises, with up to one hour of telephone support
from a vestibular therapist, will be a) more effective than
routine care in reducing symptoms (and therefore also
disability and handicap) in dizzy patients in primary care,
and b) less costly than routine care of dizzy patients.
￿ Hypothesis 2: Provision of a self-help booklet teaching
VR exercises, without any other support, will be a) more
effective than routine care in reducing symptoms (and
therefore also disability and handicap) in dizzy patients in
primary care, and b) less costly than routine care of dizzy
patients.
Methods/Design
Design overview
A single blind two-centre pragmatic randomized control-
led trial design will be used to compare the effectiveness
and cost-effectiveness of a) the self-help booklet with
expert telephone support and b) routine care (see Figure 1
for flow diagram of the trial design). We will also evaluate
the effectiveness and cost-effectiveness of providing the
self-help booklet alone compared with routine care. Par-
ticipants who receive the self-help booklet (with and with-
out support) will be asked to carry out the exercises in the
booklet for up to 12 weeks. We will calculate the total
costs of treatment in each arm, including costs of the
interventions, primary care consultations and treatment,
secondary care consultations, assessment and treatment.
Symptoms, disability and handicap will be assessed by
validated questionnaires at baseline, 12 weeks after allo-
cation to treatment group, and at one year follow-up. We
will compare the change in symptoms and quality of life
and the total costs of treatment in each group of patients.
This design was chosen so it can be compared with a pre-
vious successful trial [42], and if found to be effective,
these models of delivery can be easily rolled out through
the NHS across the region and the UK.BMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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Flow diagram of the trial design Figure 1
Flow diagram of the trial design.
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Setting
The study will be carried out in 30-50 general practices
around two centres (the department of Audiology at King
Edward VII Hospital in Berkshire and the University of
Southampton), to sample differing existing models of
delivery of routine primary and secondary care. These gen-
eral practices will be sampled to include urban, suburban
and rural practices with varying levels of social depriva-
tion. Telephone support will be provided by vestibular
therapists based at the two centres, and data will be col-
lected centrally at the University of Southampton.
Sample size/power calculation
Assuming that we will achieve a treatment effect at least as
great as that in our last primary care trial (d = .41) [42], we
will need 95 patients per group to test a two-tailed
hypothesis with 80% power and 5% significance level.
Drop-out at six months in our previous primary care trial
was 8.8% (and only 4.7% in our previous self-treatment
trial), but since we have a longer follow-up we will allow
for 15 patients to drop out of each condition (14.25%),
giving a sample size of 110 in each condition (a total of
330).
This sample size should be attainable in practice, as the
two previous primary care trials using similar recruitment
methods and recruitment time scales (15 months) were
able to attain comparable sample sizes. Yardley and col-
leagues [41] identified 327 eligible patients from 10 gen-
eral practices of varying size, from which 115 were
recruited into the trial. Our last primary care trial [42] also
followed the same time scale and recruitment method,
contacted approximately 680 participants at 20 general
practices and recruited 170 participants. Based on these
numbers we would expect to contact between 981 and
1700 patients from 30-50 general practices to recruit
approximately 255 - 575 participants into the trial.
Participant recruitment and selection
Potential participants will be identified by practice staff
(with the help of a research associate who will hold hon-
orary contracts with the PCTs) searching the computerised
database of the practice. The computerised database
search will follow inclusion and exclusion screening crite-
ria that proved successful in previous primary care studies
of dizziness to safely and effectively identify patients
likely to benefit from the self-help exercises [41,42]. We
have support for patient recruitment from the Primary
Care Research Network South East, South West and West-
ern branches, and will therefore receive service support
costs for general practices taking part. Patients can also be
directly identified by their general practitioner, and post-
ers will be displayed in practices to inform patients that
they can ask to participate.
Eligible patients will be sent a letter and invitation pack
(including the information sheet and consent form) from
their GP inviting them to take part. Patients who do not
wish to take part in the trial but are happy to provide fur-
ther information are invited to complete a trial refusal slip
indicating whether they are a) no longer dizzy, b) dizzy
but feel that the treatment would not be suitable for them,
c) dizzy but do not want to take part in the trial because
the support is given over the telephone, and the patient
has hearing difficulties, or d) do not want to take part in
the trial for some other specified reason. Patients who
have consented to take part in the trial will receive a copy
of their signed consent form (also signed by the research
associate). The research associate will also keep a copy for
the trial file, and then send the original to the patient's GP
practice for inclusion with the patient's medical notes.
After baseline questionnaire assessment, patients will be
excluded prior to randomization if they report that they
are no longer dizzy, or their dizziness is not aggravated by
performing head movements (in which case their dizzi-
ness is not typical of vestibular imbalance and is unlikely
to respond to the self-help exercises). All respondents will
receive a group allocation letter, explaining which treat-
ment group they have been assigned to, or explaining that
they have not met the inclusion criteria.
Inclusion criteria
a) Patients must be 18 or over and registered at a par-
ticipating general practice.
b) Patients must have seen their GP for dizziness some
time in the past two years (Participating practice com-
puterised databases will be searched using search
terms such as: vertigo; dizziness; Meniere's disease;
balance problems; vestibular; prochlorperazine; cin-
narizine; betahistine; diuretics - terms used will vary
according to how patient data is recorded by the prac-
tice).
c) Patients must return the completed and signed con-
sent form
d) Patients must indicate in the baseline questionnaire
assessment that they still experience dizziness and that
quick head movements make them dizzy.
Exclusion criteria
a) Non-labyrinthine cause of dizziness identified by
GP (in which case patients will not benefit from the
vestibular rehabilitation exercises)
b) Medical contraindications for making normal head
movements (e.g. severe cervical disorder), in which
case patients will be unable to carry out the exercises.BMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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c) Serious co-morbidity (e.g. progressive central disor-
der, terminal illness, and moderate to severe dementia
or mental illness).
d) Moved away from practice
e) Recently deceased
f) Non-English speakers and people unable to read
and write English.
Randomization to treatment groups and blinding
Eligible patients who have signed a consent form to take
part will be randomised by an administrative assistant at
the University of Southampton with no prior contact with
the patient. The assistant will use a remote randomisation
service, such as the Trans European Network for Clinical
Trials Services (TENALEA), to generate a schedule for
assigning participants on the basis of block randomiza-
tion within practice (block size 9) after stratification for
severity of symptoms (score below 12 or 12 and above)
on the main outcome measure at baseline. To ensure that
centre effects are not confounded with therapist effects,
patients will be randomised to the three treatment groups
and to the three therapists. The research associate collect-
ing the data will remain blind to patient allocation until
after the 12 week follow up. The research associate will
then become unblinded to the name and group allocation
of a small subsample of participants who are taking part
in interviews of their experiences of using the self-treat-
ment booklets and telephone-based therapist support.
The research associate will not become unblinded to these
participant's trial number, which is the only identifier by
which outcome data are identified. The statistician analys-
ing the data will remain blind to patient allocation
throughout the trial. Blinding of patients is not possible
due to the nature of the therapy.
Trial treatment groups
Participants will be randomly assigned to receive a) the
self-help booklet with telephone support (1 × 30 minutes
followed by 2 × 15 minutes), b) the self-help booklet
without support, or c) routine care. Participants who
receive the self-help booklet will be asked to carry out the
exercises in the booklet for 10 minutes, twice a day, every
day for up to 12 weeks. Participants in all three treatment
arms will be advised in the information sheet and group
allocation letter that they remain free to seek any other
consultations or treatment they feel they need while par-
ticipating in the trial. Participants will therefore receive,
with their group allocation letter, a participant diary to
help them to keep track of the consultations and health
care they receive for dizziness related symptoms over the
forthcoming year.
a) Self help booklet with telephone support
The 110 participants randomised to receive the self-help
booklet with telephone support will receive a self-help
booklet and an invitation (by telephone) from the admin-
istrative assistant to arrange a convenient time for a 30
minute telephone call from one of two qualified vestibu-
lar therapists with experience of treating dizziness (FB and
AM), or a trainee vestibular therapist. The therapist will
talk participants through the booklet, answer questions
and concerns and advise participants how to use the
booklet for their particular problems and needs. This ses-
sion will be followed up by two 15 minute phone calls
one week and three weeks after starting self-help, to ask
about how treatment has been progressing and to advise
on how to overcome any problems, and how to make the
exercises more challenging as their symptoms improve.
Telephone support will be standardised across the three
therapists using the half-day training workshop and ses-
sion checklist employed in our previous trial [42]. Com-
bined with remote telephone delivery, standardisation
should ensure that therapist effects on outcome are mini-
mal.
The self-help booklet explains in lay terms the causes of
symptoms and why VR should help to resolve them.
Details are given of daily balance training exercises (that
involve gently increasing the speed of making normal
head movements) to carry out in the home and how to
tailor these to the particular symptoms experienced by the
individual patient. Participants are expected to carry out
the exercises for 12 weeks (by which time most recovery
that is likely to be achieved will have occurred), or until
they are asymptomatic (if this occurs in less than 12
weeks). Advice is also given on resuming activities in daily
life that may have been avoided because of dizziness. To
ensure positive but realistic beliefs, a question-and-
answer format is used to provide evidence of treatment
relevance and efficacy and to address common concerns.
To promote confidence and adherence, the booklet helps
patients to make a specific graded goal plan and written
commitment and to adapt the intervention to their symp-
toms, capabilities, and lifestyle. The booklet also provides
advice on how to monitor treatment (using a standard self
test and chart to select appropriate exercises each week),
and highlights symptoms that indicate the patient should
cease exercising and seek medical advice.
b) Self help booklet without support
The self-help booklet has been designed and evaluated so
that it can be used with or without support. Therefore,
participants randomized to receive the booklet with no
support will simply be sent the booklet to read and follow
without advice (but will be informed that if they have
concerns about the safety of exercising or experienceBMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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adverse symptoms from exercising they should contact
the research team for expert advice).
c) Routine care
Participants in the routine care arm will be managed as
normal within that practice. After the one year follow up,
participants allocated to the routine care condition will be
sent the self-help booklet on request.
Post-trial arrangements
After the trial has ended, those in the self-help booklet
groups can keep the self-help booklet they have been
given. A self-help booklet will be sent to those in the rou-
tine care group if they wish to receive one. As this study is
a trial, the telephone advice and support from the vestib-
ular therapists will not be available beyond the 12 week
treatment time outlined above for those in the self-help
booklet with telephone support group, and will not be
available for those in the other groups (this is stated in the
Information Sheet). All groups will continue to receive
normal medical care for the treatment of their dizziness.
At the end of the project, a lay summary of the results of
the trial will be sent to all the participating practices, and
to patients on request.
Management of trial fidelity
The design of the trial is intended to minimise centre,
therapist and practice effects on outcome. Randomisation
is at the level of the individual participant rather than
practice, since contamination is improbable (in theory,
participants receiving the booklet could show it to those
who did not receive it, but it is highly unlikely that they
would come into contact and discuss the trial and treat-
ment). Practice effects are further minimised by detailed
guidance from the research team regarding inclusion and
exclusion criteria for patients to be invited to participate.
Since there will be numerous referring practices from each
centre, centre effects on clinical outcome should not be
significant.
Although the trial intervention is within the routine pro-
fessional competence of the three VR therapists, therapist
effects are minimised by strict manualisation of treat-
ment. The VR booklet forms the basis of treatment, and
the therapist's role is simply to ensure that the patient
understands and follows the booklet correctly, and to
answer questions and respond to concerns. Telephone
support will be standardised using a written workshop
format with example patient case scenarios published
with the paper reporting the previous trial [42]. The con-
tent of each therapist session is specified by a checklist. All
telephone support sessions will be tape-recorded, and the
research associate will examine treatment fidelity by com-
paring therapist checklists with a sample of taped sessions
to determine the accuracy of reporting completion of the
treatment protocol. Therapist effects are also likely to be
minimised by the absence of personal contact or an ongo-
ing professional relationship between the therapist and
patient.
Potential benefits and adverse effects
The trial has several anticipated benefits as well as predict-
able risks and inconveniences for patients taking part. Pre-
vious research has shown that chronic dizziness can be
treated effectively using the self-help booklet, although we
cannot guarantee that the self-help will be effective for all
patients. Benefits may also include feeling that they have
helped a medical research project. We hope the results will
be used to review current primary care services for people
with dizziness and this may result in improved services
though there is no guarantee of this. Risks and inconven-
iences include the time and effort required to carry out the
self-help exercises and complete the questionnaires
(approximately 20-25 minutes for each stage of the trial).
In addition to this, the self-help exercises require patients
to deliberately make themselves dizzy in a controlled
manner. Although some people may find this unpleasant,
the exercises cannot cause any damage to their balance
system.
Stopping rules
Since the exercises do not require any unusual or strenu-
ous movements, the risks of carrying them out are very
slight. Nevertheless, there is a remote possibility that the
exercises could bring on symptoms that could signal the
potential for serious medical consequences, specifically
cervical damage, damage to the inner ear (perilymph fis-
tula), or vertebrobasilar ischaemia. These symptoms,
which are detailed in the information sheet and in the
self-help booklet, are:
￿ A sharp, severe or prolonged pain in the neck, head
or ear
￿ A feeling of fullness in the ear
￿ Deafness or noises in the ear
￿ Fainting with loss of consciousness or blacking out
￿ Double vision
￿ Numbness, weakness or tingling in the arms or legs
In the very unlikely event that a participant experiences
these symptoms, they are advised (in the information
sheet, group allocation letter and self-help booklet) to
stop the exercises immediately, and consult their vestibu-
lar therapist if in the telephone support group, or the
research associate if in the booklet without support group.BMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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Problems are usually managed by advising participants to
do the exercises more slowly and gently (i.e. usually the
problems are just some non-serious aggravated neck pain
or dizziness). If thought to be necessary, participants will
be referred to their GP; however, this has not been neces-
sary in our previous clinical trials, and other clinical trials
of VR have also reported no adverse effects as a result of
undertaking VR [25].
Data collection and follow up
Participants in all three treatment arms of the trial will be
sent, by post, questionnaire packs (and a freepost return
envelope addressed to the research associate) to complete
at baseline, 12 weeks after being allocated to a treatment
group, and at one year follow up. The baseline and one
year follow up questionnaires should take approximately
up to 20 minutes to complete, and the 12 week follow up
questionnaire should take approximately up to 25 min-
utes to complete.
Self-report of service use (GP visits, medication, referral
etc.) will be checked by the research associate for accuracy
against the medical records in a random sub-sample of at
least 20 percent of patients. If significant discrepancies
between records and patient reports of service use are
found then a larger proportion will be checked if time per-
mits.
To incorporate representation of patients' views of the
trial into our evaluation, telephone-based interviews will
be conducted with 24 - 30 participants; 12 - 15 partici-
pants from the booklet only condition and 12 - 15 from
the booklet with therapist support condition. These will
take place after completion of the 12 week questionnaire,
and will last approximately 30 minutes. The interviews
will explore participants' experiences of using the self-
treatment booklets and telephone-based therapist sup-
port.
Non-responders and drop out from the trial
Non-responders to the baseline, 12 week and one year fol-
low up questionnaires will receive one postal reminder
after 3 weeks, and a follow-up telephone call (with collec-
tion of data by phone interview if preferred) for those who
still do not respond after a further 3 weeks. Dizzy patients
who volunteer to participate are typically well-motivated
to adhere to trial procedures; in our last trial we used
postal measurement of outcomes, and only 17 patients
out of 360 failed to complete the final follow-up [43]. Par-
ticipants who have chosen to drop out of the trial are
asked in the reminder letter to return the questionnaire
unanswered, so that we know that they do not want
receive the telephone reminder or further information
about the trial. Participants can either withdraw from the
trial entirely, or may choose to withdraw from carrying
out the exercises in the self-treatment booklet but still
continue to complete the follow up questionnaires. Par-
ticipants remain free to drop out of the trial at any stage,
and will not be replaced if drop out occurs after randomi-
sation. Follow-up by telephone of non-respondents will
be carried out by the blinded research associate; patients
will be advised not to reveal their trial status, and any fail-
ure of blinding will be recorded and potential effects on
trial outcomes analysed.
Outcome measures
The measures used at each data collection point are sum-
marised in Table 1. For comparability with the previous
trials of the self-help booklet, the primary outcome meas-
ure will be self-reported symptoms of dizziness, assessed
Table 1: Measures used in baseline, 12 week and one year follow-up questionnaires.
Measure Baseline 12 week One year
Demographic characteristics X
Duration of current symptoms X
Diagnosis received X
Dizziness due to head movements X
Vertigo Symptom Scale - Short Form (VSS-SF) X X X
Dizziness Handicap Inventory (DHI) X X X
Hospital Anxiety and Depression Scale (HADS) X X X
Management of dizziness 
(consultations in primary and secondary care and other sources; hospital stays; 
medication/treatment; days off work)
XX
Quality of Life (EuroQoL - EQ-5D) X X X
Your dizziness or unsteadiness now XX
Problematic Experiences of Therapy Scale
(PETS; booklet arms only)
X
Adherence to therapy (booklet arms only) X
Total time spent on each exercise (booklet arms only) X
Continuation of therapy (booklet arms only) XBMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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by the Vertigo Symptom Scale - Short Form [46], which
assesses frequency of fifteen dizziness-related symptoms
during the past month on a five point scale. A recent study
has suggested that the Vertigo Symptom Scale - Short
Form has a stable and reliable two factor structure, relat-
ing to vertigo and autonomic anxiety [47]. As it is of clin-
ical interest to be able to discriminate between symptoms
resulting from vertigo and secondary symptoms due to
autonomic anxiety, these subscales will therefore be
explored as secondary outcomes.
Secondary analyses will also include two less precise and
sensitive but clinically meaningful measures of symptom
improvement. Clinically significant change on the pri-
mary outcome measure questionnaire will be examined,
as in the last study, by identifying the proportion of
patients with a symptom score reduction of at least three
points. Subjective improvement in health will also be
assessed by a single item ('your dizziness or unsteadiness
now') used in the previous trials, asking whether, during
the past week, the participant felt better, much the same,
or worse than when completing the baseline assessment.
This item provides a simple patient-generated estimate of
effectiveness, corresponds well to other outcome meas-
ures, and ensures some follow-up data is obtained for
almost all participants, since patients will usually respond
to this item on the telephone even if they do not wish to
fill in a questionnaire.
Additional secondary outcomes that we will assess will be
quality of life effects of dizziness, and anxiety and depres-
sion. As in our previous studies, these will be assessed by
the Dizziness Handicap Inventory [48] and the Hospital
Anxiety and Depression Scale [49]. We will also assess
quality of life using the EuroQoL - EQ-5D [50], as this
provides data that can be compared with other conditions
and treatments. For the cost-effectiveness analyses, at one
year follow-up we will gather details from the medical
records and ask patients for retrospective reports for the
past year of dizziness-related: number of GP visits; medi-
cation taken; days off work; secondary referrals. The cost
and outcome data will be combined to estimate the incre-
mental cost per QALY of the two interventions from an
NHS perspective. Post-treatment we will assess adherence
to therapy in conjunction with the previously validated
Problematic Experiences of Therapy Scale (PETS) [43],
and at one year follow up we will also ask participants
whether they have continued to use the VR exercises. At
baseline we will also record demographic characteristics
(age, sex, years of education), duration of dizziness, diag-
nosis, and previous management of dizziness (e.g. medi-
cation, referrals).
Statistical analysis
Data entry will be carried out by the administrative assist-
ant and double checked by the research associate. The trial
will be analyzed on an intention to treat and per protocol
basis, using SPSS for Windows (SPSS Inc., Chicago) and
Stata (StataCorp). Levels of missing data will be investi-
gated, but are expected to be very low for the primary out-
come (see above). Missing data on individual items on
scales used to measure secondary outcomes will be
replaced by the blinded research associate by the mean for
that individual on that scale, provided that the majority of
items have been completed. Where relevant, outcome var-
iables will be checked for the assumption of normality. If
the assumption is not met, data transformations or equiv-
alent non-parametric tests will be conducted. Effect sizes
and confidence intervals will be reported for all tests.
Qualitative methods will be used by the research associate
to examine treatment fidelity by comparing therapist
checklists with a sample of taped sessions to determine
the accuracy of reporting completion of the treatment pro-
tocol. The research associate will also use qualitative
methods to analyse the interviews of participants' experi-
ences of using the self-treatment booklets and telephone-
based therapist support.
Primary and secondary analysis
Statistical analysis will be carried out by LY and MM at the
end of the trial who will both be blind to participants'
group allocation. The main analysis will compare patients
randomised to the self-help booklet with telephone sup-
port versus patients randomised to routine care. The anal-
ysis will be performed on the primary outcome symptom
score (the Vertigo Symptom Scale - Short Form) at 3
months after randomisation, using ANCOVA (analysis of
covariance) adjusted for symptom score at baseline. Con-
tinuous outcomes on the secondary outcome measures
will also be evaluated using ANCOVA. All continuous out-
come variables will be checked for the assumption of nor-
mality. If the assumption is not met, bias corrected and
accelerated bootstrap methods will be used to construct
confidence intervals. Binary outcomes will be compared
between the two groups using logistic regression. All anal-
yses will be adjusted for the level of the relevant outcome
variable at baseline. All analyses will also be adjusted for
any confounding variables that may differ by chance
between the two groups at baseline. These analyses will be
repeated for outcome at 12 months. Further secondary
outcome analyses will repeat the above, comparing out-
comes between patients randomised to the self-help
booklet without any other support versus patients ran-
domised to routine care.
To check our assumption that centre, therapist and prac-
tice effects do not significantly affect our primary out-
come, we will use summary measures, forest plots and
tests of interaction and heterogeneity. If there is evidence
of such effects, we will perform sensitivity analyses by
adding random effects terms to the model comparing theBMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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two groups. The study is not, however, powered for such
tests.
Cost -effectiveness analyses
For the cost-effectiveness analyses, the EuroQol - EQ-5D
data will be converted to utility values using the published
national tariff. Incremental cost effectiveness ratio (ICER)
data will be estimated. Cost effectiveness acceptability
analysis will quantify the level of uncertainty in stochastic
data. Sensitivity analysis will test the structural uncertainty
in a simple model. To determine the probability that one
intervention is cost effective relative to the other, we will
examine bootstrapped estimates of imputed mean costs,
the cost effectiveness plane of the incremental cost effec-
tiveness ratio, net benefit statistics and cost acceptability
curves. As in the clinical outcome analyses, these analyses
will be adjusted to control for the effect of any clinically
significant difference between the groups on baseline var-
iables.
Public involvement in the trial
The principal organization in the UK that represents the
interests of people with vertigo and dizziness due to ves-
tibular disorder is the Ménière's Society, a self-help group
with charitable status and over 5,500 members. The aims
of the Society include providing information and support
to members and their families, raising awareness among
health professionals and the general public, and encour-
aging research into the causes and treatment of Ménière's
disease. The most distressing symptom for most people
with Ménière's disease is vertigo and dizziness. The
Research Trustee of the Ménière's Society contributed to
the development of this proposal, and representatives of
the Ménière's Society will sit on the steering group for the
project. The Ménière's Society currently produces and dis-
tributes the booklets that will be used in the trial, and will
work to disseminate the trial findings and the booklets to
people with vertigo and health professionals if the inter-
vention is confirmed as effective.
Trial management
Each centre team will meet monthly, and the whole team
will meet 4 times a year. Because of the geographical dis-
persion of the team, for rapid communication between
meetings email will be most efficient. The research associ-
ate will circulate a monthly update to review progress rel-
ative to the project plan, highlighting any issues that need
to be addressed. Each team member will consult the other
team members immediately by email and/or phone on
any issues that arise.
Trial steering committee
Management of the project will be overseen by a steering
group including members who are independent of the
research team (including the Director and Research Trus-
tee of the Ménière's Society, and a neuro-otological
expert), who will scrutinise the progress and conduct of
the research annually.
Ethical approval and data protection
The trial will be conducted, analysed and reported in
accordance with the ethical principles described in the
Declaration of Helsinki, ICH Guidelines for Good Clini-
cal Practice, and the CONSORT Statements. Ethical
approval for the trial has been given by the Southampton
and South West Hampshire (B) REC, reference number
08/H0504/31. R&D and data protection approval has also
been obtained from the relevant geographical areas.
Indemnity cover is provided by the University of South-
ampton. All patients will receive an information sheet
about the trial, and written consent will be obtained from
all patients before entering into the trial. Consent will
include permission to access relevant sections of partici-
pants' medical records, to audio-tape the telephone sup-
port sessions, and to inform participants' GPs of their
participation in the trial. Participants are informed that
they remain free to withdraw from the trial at any time.
All information collected during the course of the research
will be kept strictly confidential, although source data will
be subject to monitoring, audits and REC reviews. There-
fore any information taken from medical records will
have the name and address removed when it leaves the
general practice, and participants will not be identifiable
in any report or publication. Data will be handled, proc-
essed, stored and destroyed following procedures in keep-
ing with the Data Protection Act 1998. Data from this
study will be kept for 10 years either at the University of
Southampton or a secure offsite location, and will then be
disposed of securely.
Reporting and dissemination
We will disseminate the findings of the research to three
key populations: lay people with dizziness (who need to
be informed about the availability and effectiveness of
treatment); primary care professionals (particularly GPs),
who could implement provision of VR in primary care;
and clinicians currently treating dizziness in secondary
care, who could provide expert support for treatment in
primary care. We will disseminate our findings to lay peo-
ple with vertigo and dizziness nationally and internation-
ally through the newsletter and web pages of the Ménière's
Society, and through press releases and media interviews.
We will disseminate our findings to primary care profes-
sionals nationally and internationally by submitting aca-
demic papers to journals such as the British Medical
Journal and articles to magazines such as Pulse and Doc-
tor. We will disseminate our findings within the region
through local postgraduate meetings and ENT seminars
for GPs, and by giving reports of our findings to primary
care trust managers and practice-based commissioning
groups as appropriate. We will also seek to present ourBMC Ear, Nose and Throat Disorders 2009, 9:13 http://www.biomedcentral.com/1472-6815/9/13
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findings at regional and national meetings of the Society
for Academic Primary Care, and at the North American
Primary Care Research Group Conference. We will dis-
seminate our findings to those currently involved in the
management of vertigo and dizziness (e.g. clinical scien-
tists in audiology, hearing therapists, physiotherapists,
ENT consultants, neurologists, and audiological physi-
cians) by submitting academic papers to journals such as
the International Journal of Audiology and Clinical
Otolaryngology, and magazines such as ENT News. We
will also present talks at relevant regional and national
meetings and conferences (e.g. national Balance Interest
Group meetings of physiotherapists and clinical scientists
in audiology, conferences of the international Barany
Society and British Academy of Audiology).
Discussion
The interventions we propose to evaluate in this trial are
both based on a self-help booklet that patients with dizzi-
ness can use to carry out rehabilitation. If our trial shows
that patients can cost-effectively manage their dizziness in
primary care, using a booklet with or without expert tele-
phone support, then these models of delivery can be eas-
ily rolled out through the NHS across the region and the
UK. The primary outcome would be rapid relief of the
symptoms of the large number of patients in primary care
who currently have chronic, untreated, disabling dizzi-
ness.
The cost of producing the self-help booklet is less than 50
p, so booklets could be very easily provided to any prac-
tices that wished to use them. To maximize efficient and
safe use of these booklets, patients could be screened by
their GP to exclude sinister pathology and contraindica-
tions to exercise, provided with the booklet (with or with-
out expert support), and then referred on to secondary
care for specialist assessment and treatment only if reha-
bilitation fails to relieve their symptoms. If the most cost-
effective model is to also provide expert telephone sup-
port, this can be easily provided by physiotherapists, hear-
ing therapists and clinical scientists in audiology who
have the relevant training and experience; there are
already large numbers of suitably qualified people, cur-
rently working mainly in secondary care settings.
The proposed models of care would further the aims of
the NHS Improvement Plan by providing a service based
on supported self-management. Demonstration of a cost-
effective model for managing dizziness in primary care
also has the potential to reduce the cost to the NHS of
treating dizziness by reducing demand for referral to sec-
ondary care for specialist assessment and treatment. If
patients can be treated promptly in primary care they may
be less likely to develop psychological and physical seque-
lae that cause handicap and require treatment.
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